Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -63.23M | -61.98M | -71.54M | -81.89M | -92.01M |
| Total Depreciation and Amortization | 4.91M | 4.93M | 4.93M | 4.59M | 3.78M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.03M | 14.46M | 15.53M | 18.12M | 21.36M |
| Change in Net Operating Assets | 4.97M | 34.76M | 36.91M | 39.91M | 43.69M |
| Cash from Operations | -35.32M | -7.84M | -14.17M | -19.27M | -23.18M |
| Capital Expenditure | -1.62M | -1.77M | -4.29M | -12.90M | -20.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.43M | -57.77M | -71.56M | 53.24M | 77.51M |
| Cash from Investing | -19.06M | -59.54M | -75.85M | 40.35M | 57.12M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.99M | 74.99M | 74.94M | 145.00K | 162.00K |
| Repurchase of Common Stock | -4.31M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.70M | -32.90M | -32.44M | -26.76M | -25.67M |
| Cash from Financing | 42.98M | 42.10M | 42.50M | -26.62M | -25.51M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.39M | -25.29M | -47.52M | -5.54M | 8.43M |